Hydroxychloroquine in Covid-19: Does the end justify the means?

Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone

“…Hydroxy-chloroquine (HCQ) and chloroquine (CQ) are quinoline-based antiplasmodial drugs with repurposing potential for treating COVID-19. Several in silico , in vitro, in vivo , and clinical studies have reported the efficacy of chloroquine for treating SARS-CoV-2 infections [ [72] , [73] , [74] , [75] , [76] , [77] , [78] ], and it has received US Food and Drug Administration (FDA) authorization for compassionate use in COVID-19 patients. In addition to reducing the viral load, chloroquine also exhibited anti-inflammatory [ 79 ], antiproliferative [ 80 ], and immunomodulatory [ 81 ] activities.…”

A review of potential treatments to date in COVID-19 patients according to the stage of the disease

“…Although some argue that Hydroxychloroquin (HCQ) can be used early in Stage 1. This use may have negative effects regarding loss of immunization chances due not only to its reduction of viral load, but also to its mmuno-suppressive characteristics [31].…”

Two years of COVID-19: A summary about the implication of current research in translational medicine in the efforts against the pandemic

“…The article emphasized that before the healthcare community commits to indiscriminate use of antimalarial drugs in minimally symptomatic or asymptomatic individuals, there is an urgent need to prioritize assessment of anti-Covid-19 cellular and humoral immunity in patients who have already received said drugs. [1] …”